US2015276761A1PendingUtilityA1

Methods for diagnosing pulmonary hypertension

Assignee: UNIV JOHNS HOPKINSPriority: Dec 18, 2006Filed: Apr 3, 2015Published: Oct 1, 2015
Est. expiryDec 18, 2026(~0.4 yrs left)· nominal 20-yr term from priority
A61P 29/00A61K 2039/505G01N 2500/02G01N 33/54306C07K 16/22G01N 33/6884C07K 16/40G01N 2333/912G01N 2333/4703C12Y 207/10002G01N 2333/47G01N 33/74G01N 2800/122C12N 9/1205G01N 2800/7038C07K 16/18C07K 14/4702G01N 2800/12A61P 11/00
43
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Hypoxia induced mitogenic factor (HIMF) is a member of the “found in inflammatory zone” (FIZZ)/resistin family of proteins and has potent mitogenic, angiogenic, and vasoconstrictive effects in the lung vasculature. The receptor/binding partners for this family of proteins have been largely unknown. We identified Bruton's tyrosine kinase (BTK) as a functional HIMF binding partner through GST-HIMF pull-downs and mass spectrometry. Using primary cultured HIMF-stimulated murine bone marrow cells, we demonstrated that BTK was recruited to the leading edge of the cells. We also demonstrated that BTK and the closely related tyrosine kinase Fyn, colocalized at the growth cone process in these cells. HIMF stimulation induced BTK autophosphorylation, which peaked at 2.5 minutes. A transwell migration assay showed that treatment with recombinant murine HIMF induced migration of primary cultured bone marrow cells, which was completely blocked by the BTK inhibitor, LFM-A13. In vivo studies, using the rat hindlimb ischemia model, revealed that HIMF can stimulate angiogenesis in the hypoxic tissue probably through inducing the migration of endothelial progenitor cells (EPCs) to areas of active angiogenesis. Our results indicate that HIMF may acts as a chemotactic molecule in stimulating the migration of leukocytes/EPCs from bone marrow to targeted tissues through activation of the BTK pathway.

Claims

exact text as granted — not AI-modified
1 - 23 . (canceled) 
     
     
         24 . A method to diagnose pulmonary hypertension in a subject, comprising:
 (a) determining the amount of HIMF (SEQ ID NO: 1 or 2) in a serum sample of a subject using an enzyme-linked immunosorbent assay that comprises an antibody that specifically binds Resistin or RELMbeta; and   (b) diagnosing pulmonary hypertension in the subject based on elevated levels of HIMF as compared to normal control subjects who do not have pulmonary hypertension.   
     
     
         25 . The method of claim  1 , further comprising the step of administering to the subject an antibody which specifically binds to HIMF (SEQ ID NO: 1 or 2).

Join the waitlist — get patent alerts

Track US2015276761A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.